Evidence map›Paper›PMID 41299807›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.

Jiaqi Zhang, Xiaoshu Zhu, Jiamei Qiu, Houhui Shi, Yuting Liu, Jiake Hua, Xushuang Qin, Shanni Dong, Yang Liu, Cuiyun Wu and 1 more

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiaqi Zhang *Cancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Xiaoshu Zhu *Cancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Jiamei Qiu *Cancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Houhui ShiCollege of Pharmaceutical science, Zhejiang University of Technology, Hangzhou, 310032, People's Republic of China.
Yuting LiuCancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Jiake HuaCancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Xushuang QinThe Second Clinical Medical College of Hangzhou Normal University (Zhejiang Provincial People's Hospital), Hangzhou, Zhejiang, People's Republic of China.
Shanni DongCancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Yang LiuCancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. liuyang1@hmc.edu.cn.
Cuiyun WuCancer Center, Department of Radiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. 2021110001@hmc.edu.cn.
Jun ChenCancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. chenjun@hmc.edu.cn.

Funding

The Medical Science and Technology Project of Zhejiang Province 2023KY485The Medical Science and Technology Project of Zhejiang Province 2025KY561The Natural Science Foundation of Zhejiang Province LTGY23H180018
6 · The paper itself

Abstract

purposeTo evaluate the diagnostic performance of an integrated model using intratumoral habitat imaging and peritumoral CT radiomics for preoperative noninvasive prediction of Glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC).​​.

methodsA retrospective analysis was performed on preoperative contrast-enhanced CT images and corresponding GPC3 immunohistochemical expression data from 203 patients with pathologically confirmed HCC. Intratumoral habitat features and peritumoral radiomics features (defined within 5 mm and 8 mm expansion regions from the tumor boundary) were extracted from the CT images. A nomogram was constructed by integrating the habitat Risk score, peritumoral radiomics Rad-score, and selected clinical indicators (including Edmondson grade and microvascular invasion). The diagnostic performance of these radiomics signatures was rigorously assessed through multiple analytical approaches, including discrimination accuracy measured by the area under the receiver operating characteristic curve (AUC) with statistical comparison using DeLong’s test, calibration accuracy evaluated via Hosmer-Lemeshow testing, and clinical utility determined by decision curve analysis across relevant probability thresholds.

resultsThe combined GPC3-RadNomogram model demonstrated significantly superior predictive performance compared to other models in both training and validation cohorts. The AUC values were 0.912 (95% CI: 0.866–0.958) and 0.927 (95% CI: 0.861–0.993) for the training and validation sets, respectively. Hosmer-Lemeshow tests yielded p-values > 0.05 in both cohorts. Decision curve analysis confirmed significant net clinical benefit across clinically reasonable threshold probabilities (15% − 60%). DeLong’s test revealed that habitat features provided significantly higher discriminative power for GPC3 expression than clinical models and peritumoral radiomics models in both cohorts (P < 0.001, |z|>1.96), displaying improved calibration and clinical practicality.

conclusionsThe CT radiomics model based on habitat analysis enables improved prediction of GPC3 expression in HCC by integrating heterogeneity quantification of intratumoral habitats, peritumoral microenvironment features, and clinicopathological indicators.

Indexed as

Carcinoma, HepatocellularGlypicansLiver NeoplasmsNomogramsTomography, X-Ray ComputedAgedFemaleHumansMaleMiddle AgedRadiomicsRetrospective StudiesGlypicansGPC3 protein, humanComputed tomographyGlypican-3HabitatHepatocellular carcinomaRadiomics

Identifiers

PMID41299807
PMCPMC12752380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.